Department of Cellular and Molecular Physiology, Pennsylvania State University College of Medicine, Hershey, PA, USA.
Cancer Biol Ther. 2012 Apr;13(6):358-68. doi: 10.4161/cbt.19241. Epub 2012 Apr 1.
Numerous studies have demonstrated a link between elevated polyamine biosynthesis and neoplastic growth, but the specific contribution of spermine synthase to epithelial tumor development has never been explored in vivo. Mice with widespread overexpression of spermine synthase (CAG-SpmS) exhibit decreased spermidine levels, increased spermine and a significant rise in tissue spermine:spermidine ratio. We characterized the response of CAG-SpmS mice to two-stage skin chemical carcinogenesis as well as spontaneous intestinal carcinogenesis induced by loss of the Apc tumor suppressor in Apc (Min) (/+) (Min) mice. CAG-SpmS mice maintained the canonical increases in ornithine decarboxylase (ODC) activity, polyamine content and epidermal thickness in response to tumor promoter treatment of the skin. The induction of S-adenosylmethionine decarboxylase (AdoMetDC) activity and its product decarboxylated AdoMet were impaired in CAG-SpmS mice, and the spermine:spermidine ratio was increased 3-fold in both untreated and 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated skin. The susceptibility to 7,12-dimethylbenz[a]anthracene (DMBA)/TPA skin carcinogenesis was not altered in CAG-SpmS mice, and SpmS overexpression did not modify the previously described tumor resistance of mice with targeted antizyme expression or the enhanced tumor response in mice with targeted spermidine/spermine-N ( 1) -acetyltransferase expression. CAG-SpmS/Min mice also exhibited elevated spermine:spermidine ratios in the small intestine and colon, yet their tumor multiplicity and size was similar to Min mice. Therefore, studies in two of the most widely used tumorigenesis models demonstrate that increased spermine synthase activity and the resulting elevation of the spermine:spermidine ratio does not alter susceptibility to tumor development initiated by c-Ha-Ras mutation or Apc loss.
大量研究表明,多胺生物合成水平升高与肿瘤生长之间存在关联,但精脒合酶(spermine synthase)在上皮性肿瘤发生发展中的具体作用从未在体内进行过探索。广泛过表达精脒合酶的小鼠(CAG-SpmS)表现出精脒水平降低、精胺水平升高以及组织中精胺/精脒比值显著上升。我们对 CAG-SpmS 小鼠在化学诱导的皮肤二阶段肿瘤发生中的反应以及 Apc 肿瘤抑制基因缺失(Apc(Min)(/+)(Min))小鼠自发的肠道肿瘤发生进行了研究。CAG-SpmS 小鼠对皮肤肿瘤促进剂的处理仍然表现出典型的 ornithine decarboxylase(ODC)活性、多胺含量和表皮厚度增加。然而,在 CAG-SpmS 小鼠中,S-adenosylmethionine decarboxylase(AdoMetDC)活性及其产物脱羧化的 AdoMet 的诱导受到损害,未经处理和 12-O-十四烷酰佛波醇-13-乙酸酯(TPA)处理的皮肤中的精胺/精脒比值分别增加了 3 倍。CAG-SpmS 小鼠对 7,12-二甲基苯并[a]蒽(DMBA)/TPA 皮肤致癌作用的敏感性没有改变,过表达 SpmS 也没有改变靶向抗酶表达小鼠的先前描述的肿瘤抗性或靶向 spermidine/spermine-N(1)-acetyltransferase 表达小鼠的增强肿瘤反应。CAG-SpmS/Min 小鼠的小肠和结肠中也表现出精胺/精脒比值升高,但它们的肿瘤数量和大小与 Min 小鼠相似。因此,在两种最广泛使用的肿瘤发生模型中的研究表明,增加的精脒合酶活性和由此导致的精胺/精脒比值升高不会改变由 c-Ha-Ras 突变或 Apc 缺失引发的肿瘤发生的易感性。